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Background: Small vessel disease (SMD) remains a major challenge because of the increased risk of restenosis. We
sought to assess the efficacy and safety of a paclitaxel-eluting balloon (PEB) in patients with SMD.
Methods and Results: One-hundred and four patients with native coronary lesions in small vessels treated by using
a PEB were included in this prospective multicenter registry. In each case, after regular balloon dilatation, a larger
PEB was inflated for a minimum of 45–60 seconds. Patients were 65 10 years old, 43% diabetic, and 58%
presented acutely. Angiographic success was 93% (7% bailout BMS implantation due to coronary dissection). The
rate of major adverse cardiac events (MACE) at 12 months was 4.8% (1.9% cardiac death, 1.0% MI, and 2.9%
TLR). One definite stent thrombosis was reported at 6 months in a patient with bailout BMS implantation. At
7 months, late loss was 0.31 0.2mm. Bail-out BMS after DEB use, was an independent predictor of MACE, HR
18.74, 95%CI (2.58–135.84) and TLR, HR 30.99, 95%CI (2.79–344.07).
Conclusion: The use of this PEB for the treatment of SMDprovides excellent 1-yearoutcomeswith only 4.8%MACE.
The need for a bailout BMS was a strong predictor of MACE and TLR. (J Interven Cardiol 2015;28:430–438)
Introduction
Percutaneous coronary interventions (PCI) in
small vessels (2.8mm) account for 35–50% of
interventional procedures undertaken in patients with
coronary artery disease (CAD).1,2 In-stent restenosis
remains the main limitation and is an ongoing
challenge even in the DES era.3,4 The pathophysio-
logical explanation for this problem is that stent
implantation results in arterial injury, initiating a
vasculo-proliferative cascade and resulting in neo-
intimal hyperplasia. The neointimal thickness is
relatively constant and independent of stent size, as
demonstrated by intravascular ultrasound. As such,
absolute late luminal loss is similar across a range of
vessel diameters.5,6 As stents placed in small vessels
have less room to accommodate this growth of
neointimal tissue without an important reduction in
luminal area, the risk of significant restenosis is
high.5,6 Although DES have considerably reduced
the incidence of restenosis,7 rates remain in double
figures in this particular subgroup.4,7,8 Critical
appraisal of the published evidence highlights some
safety concerns, including delayed healing and late
endothelial dysfunction of the stented arterial
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segment which appear to underlie a spectrum of late
adverse events following DES therapy, including
stent thrombosis.9
In this specific scenario, paclitaxel-coated balloon
(PCB) catheters may be an alternative treatment
option. Although PEB therapy has shown encourag-
ing results in certain disease subtypes,10–16 what
limited data exists to date does not demonstrate a
clear role for this modality in lesions in small
vessels.17–20 The aim of this large multicenter
registry was to investigate the DIOR balloon catheter
(Eurocor GmbH, Bonn, Germany), a PEB without a
contrast agent as a drug-carrier, in the treatment of
small vessel coronary artery disease.
Methods
Patient Population. Over a period of 2 years, 104
patients with native coronary lesions in small vessels
(2.5mm) treated using the, DIOR PEB, were
included in the multicenter and prospective Spanish
DIOR registry (8 Spanish centers). The registry was
set-up to assess the efficacy and safety of the DIOR
balloon in patients with small vessel disease
(2.5mm). As a real world registry, only those
patients presenting with cardiogenic shock or angio-
graphic severe calcification were excluded.
Patients’ informed consent was obtained for the
procedure and participation in this registry.
Quantitative Coronary Angiography (QCA).
QCA measurements were undertaken by a central core
lab, using a validated edge detection system (Quant-
cor1, version 4.0, Siemens AG, Forchheim, Germany).
Angiography was performed before and after all
interventions in all participating centers. The Medina
classification was used to describe bifurcated lesions.
Angiographic successwas defined as less than50%final
residual stenosis in the treated segment and the absence
of more than type B coronary dissection postDIOR
angioplasty. Restenosis was defined as >50% angio-
graphic narrowing of a previously successfully treated
lesion.
Procedure and Study Drug-Eluting Balloon
(DIORTM). A uniform technical approach was
adopted by the study centers prior to the beginning
of the study. Following selective catheterization of the
culprit vessel, intracoronary nitroglycerin at a dose of
200mgr was administered. Coronary angiography was
performed with at least 2 (for the right coronary artery)
or 3 (for the left coronary artery) orthogonal views
showing the target lesion free of foreshortening and
vessel overlap.
Dilatation of the target lesion was performed in all
cases before the study intervention, with the use of a
nonstudy balloon. A cutting balloon was used, at the
discretion of each operator. The recommended ratio
balloon: artery size was 0.8:1 with a length 5mm
shorter than that of the study balloon, DIORTM.
Careful inflations with increasing pressures were
advised to avoid dissections. Once an optimal
dilatation result was obtained (residual stenosis less
than 50%, without flow-limiting dissection, less than
type B coronary dissection), a 5mm longer DIORTM
balloon was strongly recommended to avoid a
“geographical miss” effect. Details of the study
balloon DIORTM have been given elsewhere.10,21,22
In this registry, we used both generations of DIORTM
balloons which share most general properties: the drug
and the dose of paclitaxel, the balloon designed with
3-folds of microporous surface ensuring good contact
with paclitaxel, and a similar preparative process.
However, the coating method is different. The first
generation DIOR balloon had a nanoporous surface-
containing microcrystals of pure paclitaxel that were
then embedded on the vessel wall at the time of
balloon inflation.10,21 The second generation DIOR
balloon contains shellac as a paclitaxel carrier.
Shellac is an inert substance that has already been
approved by the FDA as a food additive. It is mostly
composed of aleuritic acid, jalaric acid, and shelloic
acid. The microporous balloon surface contains a 1:1
mixture of paclitaxel and shellac. A balloon inflation
time dependency study in the porcine model of
coronary artery overstretch showed almost maximum
tissue paclitaxel concentrations after shorter balloon
inflation times of 30 seconds and release of 75% of
the drug from the balloon surface, which resulted
significantly higher drug concentration after 45mi-
nutes when compared with the first generation
DIOR22 (Fig. 1). DIORTM, was used to deliver the
antiproliferative drug to the vessel wall, and inflated
in the same fashion as a conventional balloon. The
ratio balloon:artery recommended was 1:1 and
the recommended dilatation pressure was just above
nominal pressure. The recommended inflation time
was from 45 to 60 seconds for the second and first
DIOR, respectively. So as to evaluate the absence of
acute recoil, a final angiographic image was
recommended 5–7minutes after DIOR angioplasty.
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Stenting with a bare metal stent (BMS) was used only
for the following indications: >type B coronary
dissection, acute coronary occlusion, and acute recoil
with residual stenosis more than 50%. In these cases,
the type of BMS selected was left to the operator’s
discretion (Fig. 2).
Antithrombotic Therapy. Postprocedure patients
were prescribed clopidogrel, 75mg daily for at least
1 month and aspirin 100mg p.o. daily indefinitely.
Patients with a contraindication to dual antiplatelet
therapy took either Aspirin 100mg daily or clopidogrel
75mg daily.
Study Definitions. Small vessel disease was
defined as lesions within coronary arteries with a
diameter of 2.5mm by visual estimation. Myocar-
dial infarction (MI) was defined as CPK elevation 3
times the upper limit of normal. Post-procedural CPK
was only measured in case of symptoms and/or
Figure 1. Second generation paclitaxel-eluting balloon design, DIORTM.
Figure 2. Study’s flowchart.
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electrocardiogram changes suggesting MI. Target
lesion revascularization (TLR) was defined as any
repeat percutaneous intervention or surgical bypass of
the target lesion performed for>50% restenosis of the
treated segment or within 5mm either end of the stent.
Restenosis was defined as >50% angiographic
narrowing of a previously successfully treated lesion.
Stent thrombosis or occlusion (ST) was defined,
according to the Academic Research Consortium
(ARC), as definite, probable, or possible and as early
(0–30 days), late (31–360 days), or very late (>1 year)
of the index PCI.23 Deaths from undetermined causes
were classified as cardiac. Major adverse cardiac
events (MACE) was a combined endpoint of cardiac
death, Q, or nonQ wave myocardial infarction (MI) or
TLR according to the device oriented MACE
definition.23
Follow-Up Procedures of Patients. All patients
were followed by clinical visit or telephone call at
1 month, 6months, and 1 year. At 6–8months, in 2 pre-
selected centers (H. Mar and H. Trias I Pujol),
angiographic follow-up was performed. By predefin-
ing these 2 centers the aim was to complete a high
proportion of angiographic follow-up (>80%) so as to
be representative of symptomatic and asymptomatic
restensosis. If a patient was lost to follow-up, the
family physician or cardiologists were contacted. In
case of failure, information about death was obtained
from the population registry (Fig. 3).
Statistical Analysis. Continuous variables are
presented as mean and standard deviation and
categorical variables as number and percentage.
Comparisons of continuous variables between groups
were made using Student’s t-test. Categorical varia-
bles were compared using either the chi-squared or
Fishers exact test. For each of the events of interest
considered, observation time started at the date of
stent implantation and ended either at the date of
occurrence of the event or on the last day of contact
depending on which occurred first. Survival curves
were estimated by the Kaplan–Meier method. Cox
proportional hazards models were fitted for selected
comparisons of outcomes by patient, lesion or
procedural characteristics. A P-value <0.05 was
considered to indicate statistical significance. Statis-
tical analysis was performed using commercially
available software (SPSS IBMS 21 for windows,
SPPS IBM, Inc., Chicago, IL).
Figure 3. The cumulative survival (CS) free of
MACE, by theKaplan–Meiermethod, for 6 and
12 months, was 96.9% (95%CI: 93.4–99.8)
and 93.3% (95%CI: 88.3–99.2), respectively.
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Results
Patient Population. A total of 104 patients were
prospectively included in the study. The population
(Tables 1 and 2) had a mean age of 65 10 years, 43%
were diabetic.Most of the patients (58%) presentedwith
an acute coronary syndrome (ACS). A total of 74% of
patients had at least 2-vessel disease and inmost of these
patients a stent was implanted outside of the target
lesion. A total of 42% of lesions-treated lesions with the
DEB involved branches of the major epicardial arteries
(bifurcated lesion), the first diagonal being the most
frequently treated lesion (31%).
Concerning the procedures (Table 3), predilatation
was undertaken in all patients with a regular balloon,
smaller in diameter and shorter in length than DIOR
balloon. The mean DIOR inflation time was around
100 seconds. Reference vessel diameter was
1.95 0.32mm and final diameter stenosis and acute
gain were 23.1 10.2% and 1.05 0.3mm, respec-
tively (Table 4).
Short- and Long-Term Outcomes. The proce-
dure was angiographically successful in 93% of
patients. In 7%, a bailout BMS was required after
Dior angioplasty because of coronary dissection more
than type B (7 cases). The stent was implanted within
the DEB treated zone in all cases. Clinical follow-up at
1 month was available for all patients and no MACE
was reported. At a median of 12 (11.1–13.1) months,
the cumulative rate of adverse events is given in
Table 5. The traditional MACE rate was only 4.8%:
cardiac death in 2 (1.9%), anyMI in 1 (1.0%), and TLR
in 3 (2.9%). The cumulative incidence of MACE is
shown in Figure 4. By our definition, 2 cardiac deaths
were reported. One was a case of sudden death at
3 months in a patient with 3 vessel disease in which a
BMS and DES were also implanted at the time of the
index procedure. The other was a case of death of
unknown cause at 7 months, in a patient with a 1,0,1
bifurcation lesion involving a first marginal branch
treated with DCB.
Angiographic Outcomes. Baseline angiograph-
ic analyses confirmed that the lesions treated were
located in really small vessels (reference vessel
diameter was 1.95 0.32mm). By protocolTable 1. Baseline Demographic and Clinical Patients Character-istics, n–¼ 104
Age, years (meanSD) 65.3 10.3
Male gender (78) 75.0
Risk factors
Diabetes mellitus (45) 43.3
Hipertension (74) 71.2
Dyslipidaemia (68) 65.4
Current smoker (34) 32.7
Renal impairment (creatinine 1.5mg/dl) (8) 6.7
History of
Myocardial infarction (25) 24.0
PCI (24) 23.1
Coronary bypass surgery (5) 4.8
Clinical presentation
Acute coronary syndrome (60) 57.7
STEMI (11) 10.6
3 vessel disease (29) 27.9
2 vessel disease (77) 74.0
LVEF 50% (mean SD) (27) 32.5
Unless specified otherwise, values are (n) and % of patients. PCI,
precutaneous coronary interventions; STEMI, <24 h of ST-segment
elevation myocardial infarction; LVEF, left ventricular ejection
fraction.
Table 2. Baseline Lesion Characteristics, n¼ 104
Small vessel indication (104) 100
SMV alone (53) 51.0
SMVþ bifucation lesion (001, 111, 011,
101)
(44) 42.3
SMVþ contraindication to DAT (7) 6.7
Target vessel treated
Fisrt diagonal branch (33) 31.7
Fisrt Marginal branch (21) 20.2
Posterior descending artery (RCA) (11) 10.6
Second Marginal branch (8) 7.7
Overall bifurcation lesion (44) 42.3




Unless specified otherwise, values are (n and %) of patients. SMV,
small vessel; DAT, dual antiplatelet therapy; aspirine plus clopidgrel.
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angiographic follow-up was mostly undertaken in 2
predefined centers (84%) that was 49.5% respect to
the overall population. Angiographic outcomes are
shown in Table 4. “In-stent” (in-balloon) late loss
was 0.31 0.2mm, with a binary in-segment
restenosis of 19.6% (10).
Predictors of Adverse Events. As is shown in
Table 6, at 12 months, by Cox multivariate analysis,
independent predictors of adverse events (MACE)
were the following: bailout BMS after DEB failure,
and STEMI as clinical presentation. Complete revas-
cularization was a protective factor for MACE.
Bifurcation lesion type was a predictor of binary
restenosis as was stent implantation outside of the
target lesion (Fig. 4). The DIOR balloon type (first vs
second generation) was not associated with adverse
event rate at follow-up.
Discussion
The main finding of this prospective multicenter
registry is that PCI for unselected patients treated for
small coronary vessel disease using the DIOR
Table 3. Baseline Procedural Characteristics, n¼ 104
Radial approach (47) 45.2
6-French guide catheter (85) 81.7
Pts with stent implanted out of the TL (57) 54.8
DES implanted out of the target lesion (46) 44.2
Complete revascularization (64) 61.5
Predilatation (plain balloon) (104) 100
Balloon diameter mm, (mean SD) 2.01  0.3
Balloon length mm, (mean SD) 15.8  4.1
Main balloon pressure mmHg, (mean SD) 12.2  3.0
Dior balloon angioplasty (104) 100
Balloon diameter mm, (mean SD) 2.2  0.2
Balloon length mm, (mean SD) 20.2  5.3
Main balloon pressure mmHg, (mean SD) 12.8  3.3
Balloon inflation time second (mean SD) 105.5  53.2
Second generation of DIOR (48) 46.1
Postdilatation after DIOR angioplasty (6) 5.8
Bail-out indication of bare metal stent (7) 6.8
Acute recoil (acute stenosis 50%) (0) 0
Coronary disection  type B (7) 100
Stopped DAT 6 months (9) 8.7
Glycoprotein IIb/IIIa inhibitor (2) 1.9
Angiographic success (97) 93.3
Unless specified otherwise, values are (n) and % of patients. Pts,
patients; TL, target lesion; DAT, dual antiplatelet therapy; aspirine
plus clopidogrel.
Table 4. Quantitative Angiographic Analysis of Lesions TreatedWith Angiographic Follow-Up at a Mean of 7.5 2.6Months (n¼ 51 Lesions;
83.6% of Angio FU Completed in 2 Centers, and 49.5% of the Overall Population)
N¼ 51 (39.3% 1st G of DIOR) Preangioplasty Postangioplasty Angio FU
Reference diameter, mm 1.95  0.32
Lesion length, mm 12.8  7.1
MLD, mm 0.49  0.28 1.54  0.34 1.23  0.53
Diameter stenosis, % 76.8  13.4 23.2  10.2 39.7  26.1
Acute gain, mm 1.05  0.3
Late luminal loss, mm 0.31  0.2
Binary restenosis, n (%) (10) 19.6
Unless specified otherwise, values are mm, (meanSD). MLD, minimum luminal diameter.
Table 5. Cumulative Nonhierarchical Major Cardiac Adverse
Events (MACE) at 1 and at a Median of 12.0 (11.1–13.1) Months
Follow-Up
Follow-Up 1 Month 12 Months
Overall death (0) 0 (3) 2.9
Cardiac (0) 0 (2) 1.9
Non-cardiac (0) 0 (0) 0
Q and nonQ wave MI (0) 0 (1) 1.0
Target lesion revascularization (0) 0 (3) 2.9
MACE (0) 0 (5) 4.8
Stent Thrombosis (ARC) (0) 0 (1) 1.0
Values are numbers (n) and% of patients. MI, myocardial infarction;
MACE, major adverse cardiac events: ARC, academic research
consortium.
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paclitaxel-coated DEB is associated with excellent
immediate and longer term results (1-year MACE of
5% with TLR 3% and 7 months late loss of 0.3mm).
This “real-world” registry is unique in including a
significant group of symptomatic patients (70% ACS)
with only one target lesion located in a really small
vessel; a significant proportion of treated lesions
involving branches of the major epicardial arteries
(42%). An additional finding is that the group of
patients treated with DCB plus additional bailout BMS
Figure 4. The cumulative survival (CS) free of TLR, by the Kaplan–Meier method, comparing “the combined strategy”DEB plus bailout-BMS
versus DEB as stand alone therapy. Mean survival time free of TLR was 10.6 (7.9–13.3) versus 26.9 (25.8–27–9.5) months, P¼ 0.007,
respectively.
Table 6. At 12 Months, We Found by Cox Multivariate Analysis That the Significant Predictor of Adverse Event Were as Shown Below
MACE HR IC 95% P-Value
DEBþBailout BMS 18.74 2.58–135.84 0.004
STEMI 9.99 1.40–71.18 0.022
Complete Revascularization 0.10 0.01–0.87 0.038
TLR
DEBþBailout BMS 30.99 2.79–344.07 0.005
Restenosis
Pts with stent implanted out of the TL 9.439 1.19–74.72 0.03
Bifurcated lesion 6.707 0.84–53.16 0.07
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implantation had a significantly worse outcome than
those treated with DCB alone. We found that bailout-
BMS after DEB angioplasty was an independent
predictor of MACE and TLR. A bigger Dior balloon
diameter was related with DEB failure and bail-out
BMS. Predictably STEMI as a clinical presentation
predicted MACE and treatment of bifurcartions was
associated with restenosis.
Small vessel disease has been defined as lesions
involving coronary arteries with a diameter of <3mm
by visual estimation. The definition includes a wide
range of vessel diameters but this is based on the lack of
benefit of BMS over with balloon angioplasty in vessels
less than 3mm.1,24 Vessel size is inversely correlated
with the risk of restenosis and adverse outcome after
percutaneous coronary interventions. This is because
the amount of neointimal hyperplasia is largely
independent of vessel size, and thus, small vessels
are more prone to restenosis than larger vessels because
they are less able to accommodate neointimal tissue
without compromising blood flow.5,6 In this paper,
we report results in patients with mean reference
diameter by visual estimation 2.25mm. Compared
with trials which include lesions placed in small vessel
(<2.8mm), we report the lowest rate of MACE (5%)
and TLR (3%) at 1 year.3,17,19,24 Moreover, DEB also
could provide a therapeutic option in very small vessels
(<2.25mm), for which DES sizes are not available.
In the ISAR SMART trial, Castrati et al. reported for
POBA group (n¼ 200) a late luminal loss of
0.72 0.71mm, with binary stent restenosis of
31.4% and TLR of 20.1% at 6–7 months, similar
results were described for the BMS group (n¼ 204).24
In the randomized trial, ISAR-SMART 3, comparing
paclitaxel (PES) (n¼ 180) versus sirolimus-eluting
stents (SES) (n¼ 180), they reported better late loss,
restenosis, and TLR results for SES group (0.25 0.55
vs 0.56 0.59mm), (11.4 vs 19.0%), and (6.6 vs
14.7%), respectively.3
Regarding trials using DEB technology, the PEP-
CAD I (n¼ 118) was the first study (single-arm
nonrandomized trial) evaluating the safety and efficacy
of the Sequent Please balloon for the treatment of
small vessel disease (mean reference diameter
2.35 0.19mm), and showed good angiographic
(late loss of 0.28 0.53mm) and clinical results at
12 months (TLR of 4.9%), thus, demonstrating that
DEB possibly yields the potential as treatment
alternative for these types of lesions.17 Two random-
ized trials have reported different results. The published
BELLO randomized trial reported that the In.Pact
Falcon DEB (n¼ 94) was noninferior to PES (n¼ 97)
in suppressing neointimal proliferation in small
vessels. Furthermore, DEB and PES were associated
with similar rates of angiographic restenosis (10.0 vs
12.6%), late loss (0.08 0.38 vs 0.29 0.44mm), and
repeat revascularisation (4.4 vs 7.6%).19,25On the other
hand, the PICCOLETO trial failed to demonstrate
DIOR I DEB equivalence to a PES for the treatment of
small vessel disease, both in terms of angiographic and
clinical restenosis. It is important to note some
procedural limitations of this study as plain balloon
predilatationwas done only in 25%of cases and bailout
stent implantation in the DEB group was 35.6% with
the occurrence of so-called “geographical mismatch,”
which led to restenosis in stented lesion sites that were
not adequately pretreated with DEB.18
In our trial we were particularly careful to use DCB
as a delivery drug system, thus lesion predilatation was
performed in all cases with a shorter plain balloon than
DIOR. Thus, bailout stent implantation was only
needed in 7.5% of cases, and in these cases
investigators were particularly careful to ensure that
any needed stent was implanted within the DEB-
treated zone. We found that bailout BMS implantation
was a strong predictor of MACE and TLR. Moreover,
we reported, that a bigger mean diameter of the DIOR
balloon (2.36 0.13 vs 2.18 0.23mm, P¼ 0.048)
was related with higher rate of bailout BMS
implantation. The main reason of DEB failure was
dissection and mean reference diameter. Thus, proba-
bly, the mean diameter of the DIOR balloon used in the
DEB plus BMS (failure group) was over sized.
According to this, the PEPCAD I, reported a
significantly higher late loss and restenosis rate in
lesions treated with a combination of DEB and bail-out
BMS, especially if geographic mismatch occurred (i.e.
stent implanted in an area that was not treated with
DEB).17 Thus, when using DCB the technique and
method of usage is important and may have a clinical
impact on the results.
Limitations of the Study. Because of the explor-
atory nature of this study, no “a priori” sample size was
calculated. In this real-world registry CPKs were only
drawn if patients were having ongoing chest pain
and/or ECG changes, thus the rate of MI and MACE
was probably underestimated. The smaller mean
reference vessel size compared with other trial using
similar technology could explain the relative higher
rate of angiographic restenosis but at the same time as
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TLRwas symptom or ischemia driven, the rate of TLR
might be lower compared to some trials with bigger
vessel reference diameter.
Conclusion
Percutaneous intervention for unselected patients
treated for small coronary vessel disease (2.25mm)
using the DIOR, paclitaxel-coated balloon, with a
predefined strategy is associated with excellent imme-
diate and long-term results. However, drug-coated
balloon technology cannot overcome the mechanical
limitation of acute recoil and flow-limiting dissections
seen sometimes after balloon angioplasty. The bailout
BMS after drug-coated balloon failure is clearly inferior
to drug-coated balloon as stand alone therapy.
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